NCT05303038: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

NCT05303038
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: 
Exclusions: Patients with brain metastases; Patients without more than 2 prior lines systemic therapy
https://ClinicalTrials.gov/show/NCT05303038

Comments are closed.

Up ↑